We have proposed a strategy to use the iPSC technology for expansion of tumor antigen specific CTLs; iPSCs produced from T cells (T-iPSCs) inherit rearranged TCR genes, and thus all regenerated T cells from T-iPSCs express the same TCR. To apply this approach in allogeneic setting, we thought of a method in which non-T cell derived iPSCs are transduced with exogenous TCR genes (TCR-iPSCs). As a source of iPSCs, we decided to use HLA-haplotype homo iPSCs; regenerated cells from such iPSCs could be transplanted to HLA-hetero recipients. At present, top four frequent HLA-haplotype homozygous iPSC lines are available in Japan, covering 35% of the Japanese population. We applied this system to the TCRs that have been used in clinical trials in Japan. Thus, the most frequent HLA-homo iPSCs were transduced with WT1-specific TCR that has been used in clinical trial of TCR gene transfer therapy against leukemia in Ehime University. Regenerated CTLs from the WT1-TCR-iPSCs suppressed growth of WT1-expressing renal cell carcinoma cells in patient-derived xenograft model. We also applied this system to NY-ESO1-TCR that has been used in clinical trial targeting synovial sarcoma or melanoma in Mie University. Regenerated NY-ESO1-CTLs showed cytotoxicity against myeloma cells in xenograft model. These results demonstrate that the TCR-iPSC method works very well; however, we decided to further improve this method, since this method still has some concerns: i) risk of damaging genome by lentiviral transduction and ii) some difficulty in controlling expression level of TCR. It is therefore preferable that an exogenous TCR gene is integrated into TCR gene locus so that it is expressed under the control of endogenous promoter/enhancer while causing no genome damage. It is also nice if we could insert a TCR gene just like “a cassette tape”. To this end, we have developed a novel method named “TCR cassette method”, in which we firstly knocked-in a “cassette deck” structure containing V-beta-promotor into TCR gene locus upstream of enhancer of TCR-beta gene in non-T derived iPSCs. We then inserted NY-ESO1-TCR as a cassette tape into the cassette deck. The resulted iPSCs gave rise to potent CTLs, confirming that this new method is applicable in producing CTLs for cell therapy against cancer.